Floatz logo

Therapeutic Asset Ratings

534 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Γδ T-Pd-1 Ab Cells
Cancer
Changzhou No.2 People's HospitalP1C (36)
sph6516 tablets
Cancer
Shanghai Pharmaceuticals Holding Co., LtdEarly P1C (36)
Ttx-Mc138-Nodaga-Cu64
Cancer
TransCode TherapeuticsEarly P1C (36)
m9466
Cancer
EMD Serono Research & Development Institute, Inc.P1C (34)
Milademetan
Cancer
Rain Oncology IncP1/2C (34)
[68Ga]Ga-R54
Cancer
National Cancer Institute, NaplesEarly P1C (33)
Biological: Innopcv
Cancer
The Affiliated Hospital Of Guizhou Medical UniversityEarly P1C (33)
gc203 til
Cancer
Shanghai Juncell TherapeuticsEarly P1C (33)
Hs-It101
Cancer
The Affiliated Hospital of Qingdao UniversityEarly P1C (33)
ibr900 cell
Cancer
Beijing Boren HospitalEarly P1C (33)
kt095 car-t
Cancer
The First People's Hospital of LianyungangEarly P1C (33)
mb1707
Cancer
Mainline Biosciences, Inc.Early P1C (33)
mpt0b640
Cancer
J Ints BioEarly P1C (33)
Personalized Neoantigen Tumor Vaccine
Cancer
Ruijin HospitalEarly P1C (33)
TIL
Cancer
Shanghai Juncell TherapeuticsEarly P1C (33)
Vobramitamab Duocarmazine
Cancer
MacroGenicsP1D (28)
Pralsetinib, trans-
Cancer
Seoul National University Bundang HospitalD (26)
afm24
Cancer
Affimed GmbHP1/2D (23)
Bgb-3245
Cancer
SpringWorks Therapeutics, Inc.P1/2D (23)
ak-1286
Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.P1NR (0)
D3L-002
Cancer
D3 Bio (Wuxi) Co., LtdP1NR (0)
jh021
Cancer
Biotech Pharmaceutical Co., Ltd.P1NR (0)
km257 bispecific antibody
Cancer
Xuanzhu Biopharmaceutical Co., Ltd.P1NR (0)
km602
Cancer
Xuanzhu Biopharmaceutical Co., Ltd.P1NR (0)
nb002
Cancer
Suzhou Neologics Bioscience Co., Ltd.P1NR (0)
Showing 501 to 525 of 534 assets
PreviousPage 21 of 22Next